

Amanda Harris Corbett, Pharm.D., BCPS

OFFICE: School of Pharmacy **HOME:** 12033 Wicker Drive
CB# 7360, 3317 Kerr Hall Chapel Hill, North Carolina
The University of North Carolina 27517
Chapel Hill, North Carolina (919) 240-4029
27599-7360
(919) 843-2280

EDUCATION

August 1995-May 1999 **Doctor of Pharmacy**
Campbell University
School of Pharmacy
Buies Creek, North Carolina

August 1990-December 1994 **Bachelor of Science in Chemistry**
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

LICENSURE

Licensed Pharmacist State of North Carolina #14881

TRAINING

July 2001- June 2003 **Infectious Diseases Pharmacotherapy Fellow**
University of North Carolina at Chapel Hill
School of Pharmacy
Director:
Angela D.M. Kashuba, BScPhm, PharmD, DABCP

July 2000-June 2001 **Infectious Diseases Pharmacy Resident**
Clinical Instructor, School of Pharmacy
University of North Carolina at Chapel Hill
UNC Healthcare
Co-Directors:
Ralph H. Raasch, PharmD, BCPS, FACCP
John C. Rublein, PharmD, BCPS

July 1999-June 2000 **Pharmacy Practice Resident**
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Director: James R. Beardsley, PharmD, BCPS

PROFESSIONAL EXPERIENCE

- Oct 2007-present* **Clinical Assistant Professor**
University of North Carolina at Chapel Hill
School of Medicine
Chapel Hill, North Carolina
- July 2003-present* **Clinical Assistant Professor**
University of North Carolina at Chapel Hill
School of Pharmacy
Chapel Hill, North Carolina
- Jan 2005-present* **Clinical Associate**
Center for AIDS Research
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
- Jan 2004-Dec 2006* **Co-investigator**
Adult AIDS Clinical Trials Group,
Pharmacology Support Laboratory
University of North Carolina at Chapel Hill
School of Pharmacy
Chapel Hill, North Carolina
- July 2000-June 2003* **Clinical Instructor**
University of North Carolina at Chapel Hill
School of Pharmacy
Chapel Hill, North Carolina

PROFESSIONAL AFFILIATIONS

1. University of North Carolina, Center for AIDS Research (2003-present)
2. Adult AIDS Clinical Trials Group (2004-present)
3. American College of Clinical Pharmacy, Infectious Diseases PRN (2003-present)
4. Infectious Diseases Society of America (2002-present)
5. International AIDS Society (2002-present)
6. Society of Infectious Diseases Pharmacists (2000-present)
7. American College of Clinical Pharmacy (1999-present)
8. North Carolina Association of Pharmacists (1999-2002)
9. Kappa Psi Pharmaceutical Fraternity (1997-present)
10. Phi Lambda Sigma Leadership Society (1996-1999)
11. American Society of Health System Pharmacists (1995-2002)
12. Gilead Sciences Advisory Board (2006-present)
13. Abbott Laboratories Advisory Board (2006-present)
14. Bristol Meyers Squibb Advisory Board (2007-present)

GRANTS

1. Kashuba ADM, Principal investigator. **Corbett, AH, Co-investigator.** Bristol-Myers Squibb Company. Nov 2006-June 2007. \$187,932.
2. van der Horst C, Principal investigator. **Corbett, AH, Co-investigator.** HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health. Centers for Disease Control, Special Interest Project 13-01. Oct 2001-Sept 2008. \$350,000.
3. Quinlivan EB, Principal investigator. **Corbett, AH, Co-investigator.** Ryan White Comprehensive AIDS Resources Emergency Act Title III Grant. US DHHS/Health Resources and Services Administration/HIV/AIDS Bureau. Sept 06-March 2012
4. **Corbett AH, Principal investigator.** American College of Clinical Pharmacy, Sanofi-Aventis Infectious Diseases Investigator Development Research Award. Antiretroviral Pharmacology in Malawian Children. July 2004-June 2005. \$15,000.
5. **Corbett AH, Principal investigator.** UNC University Research Council Research Grant. Antiretroviral Pharmacology in Malawian Children. University of North Carolina, University Research Council. May 2004-April 2006. \$3961.
6. **Corbett AH, Principal investigator.** UNC Center for AIDS Research Developmental Award. Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children: Triomune tablets versus generic liquids versus trade liquids. University of North Carolina, CFAR. June 2004-May 2005. \$11,526.
7. **Corbett AH, Principal investigator.** UNC School of Pharmacy Faculty Seed Grant. Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian children: Triomune tablets versus generic liquids versus trade liquids. University of North Carolina, School of Pharmacy and Pharmacy Foundation of North Carolina. April 2004-May 2005. \$9700.
8. **Corbett AH, Principal investigator.** Junior Development Award. Antiretroviral Pharmacokinetics in Malawian Children. University of North Carolina, Committee on Faculty Research and Study Leaves. Jan 2004-Dec 2004. \$5000.00.
9. Kashuba ADM, Principal investigator. **Corbett AH, Co-investigator** University of North Carolina ACTU Pharmacology Support Laboratory. Adult AIDS Clinical Trials Group. DAIDS (NIH). 2004-2006. \$280,000.00
10. Kashuba, ADM, Principal Investigator, **Corbett AH, Co-investigator.** Eron J, Co-Investigator. The Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir, Lopinavir and Ritonavir in Healthy Volunteers. GlaxoSmithKline (Investigator Initiated Research), 2002-2003. \$59,000.00.
11. Kashuba ADM, Principal Investigator. **Corbett AH, Co-investigator.** Ortho-McNeil Infectious Diseases Academic Fellowship. American College of Clinical Pharmacy. 2002 – 2003 \$20,000.00.

RESEARCH INITIATIVES

1. "Early access of MK-0518 in combination with an optimized background antiretroviral therapy (OBT) in highly treatment experienced HIV-1 infected patients with limited or not treatment options"
2. "Early access of TMC125 in combination with other antiretrovirals in treatment experienced HIV-1 infected subjects with limited treatment options"
3. "Pharmacokinetic comparison of two generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV infected Malawian children: Triomune™ tablets versus generic liquids versus trade liquids" in collaboration with Mina Hosseinipour, MD; Peter Kazembe, MD; Irving Hoffman, PA
4. "Assessment of pharmacologic treatments of HIV/AIDS and associated outcomes using the North Carolina-AIDS drug assistance program (ADAP) database" in collaboration with Emily Brouwer (PharmD candidate); Peter Leone, MD; Sonia Napravnik, PhD
5. "A retrospective comparative analysis of the immunologic and virologic response to Fuzeon™ (enfuvirtide; T-20) versus optimized background in HIV infected patients-after the TORO trials" in collaboration with Leslie Prichard(PharmD candidate), Sonia Napravnik, PhD; Joseph Eron, MD; Prema Menezes, PA.
6. Protocol Pharmacist for "ACTG 5221: A strategy study of immediate versus deferred initiation of antiretroviral therapy for HIV-infected persons treated for tuberculosis with CD4<200cells/mm³".
7. Protocol Pharmacist for "ACTG 5225: A phase I/II dose finding study of high dose fluconazole treatment in AIDS-associated cryptococcal meningitis".
8. Co-investigator and Coordinator for "BI 1182.70: An open-label non-randomized treatment protocol of tipranavir co-administered with low dose ritonavir (TPV/r) in protease inhibitor-experienced patients with HIV-1 infection (the tipranavir expanded access program)".
9. Co-investigator and Coordinator for "A comparison of alternative injection devices to the standard subcutaneous needle/syringe combination for enfuvirtide (Fuzeon®)"

PUBLICATIONS

1. Jung B, Rezk N, Bridges A, **Corbett A**, Kashuba A. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr* 2007;21:1095-1104.
2. **Corbett A**. Opportunistic Infections in HIV Infected Patients in 9th Edition of *Applied Therapeutics : The Clinical Use of Drugs* (in press)
3. Dumond J, Yeh R, Patterson K, **Corbett A**, Jung B, Rezk N, Bridges A, Stewart S, Cohen M, Kashuba A. Antiretroviral drug exposure in the female genital tract:

implications for oral pre- and post-exposure prophylaxis. *AIDS* 2007;21(14):1899-907.

4. Pastakia S, **Corbett A**, Raasch R, Napravnik S, Correll T. High frequency of HIV-related medication errors and associated risk factors in hospitalized patients. *Annals of Pharmacotherapy* (in review).
5. **Corbett A**, Yeh R, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in *Pharmacotherapy: A Pathophysiological Approach and Pharmacotherapy Principles and Practice*.
6. Hosseinipour MC, **Corbett AH**, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, and Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV infection in Malawi. *AIDS* 2007;21(1):59-64.
7. **Corbett AH**, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba ADM. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. *Antimicrob Agents Chemother* 2006;50:2756-61.
8. **Corbett A**, Yeh R, Dummond J, Kashuba A. Human Immunodeficiency Virus in *Pharmacotherapy Principles and Practices*.
9. Min SS, **Corbett AH**, Rezk NL, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. Protease inhibitor and non-nucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. *J Acquir Immun Defic Syndr* 2004;37:1577-80.
10. **Corbett AH**, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. *J Acquir Immun Defic Syndr* 2004;36:921-928.
11. Catanzaro L, **Corbett A**, Kashuba A, Shafer R, Hewitt RG, Acosta E, and Morse GD. HIV-1 Protease Inhibitors, in *Antimicrobial Therapy and Vaccines, Vol. II*. Yu VL, et al. (eds), New York: Apple Trees Production, 2003.
12. **Corbett AH**, Kashuba ADM. Ask the Experts - Combining Saquinavir with Lopinavir/ritonavir. www.medscape.com, Sept 2002.
13. **Corbett AH**, Lim ML, Kashuba, ADM. Kaletra™ (Lopinavir/Ritonavir). *Annals of Pharmacotherapy*, 2002;36(7/8):1193-1203.
14. **Corbett AH**, Kashuba ADM. Fosamprenavir. *Current Opinion in Investigational Drugs*, 2002;3(3):384-390.
15. **Corbett AH**, Kashuba ADM. Ask the Experts – Treatment of Nelfinavir-Associated Diarrhea. www.medscape.com, Jan 2002.

16. **Corbett AH**, Rublein JC. DAPD. *Current Opinion in Investigational Drugs*, 2001;2(3):348-353.
17. **Corbett AH**. Treatment of End Stage AIDS. *Pharmacy Times* 2000;47,48,53.
18. Farina RD, **Corbett AH**, Edwards MD, Kendrick SM. Osteoporosis Screening: Is screening effective? Can it be done economically? Will people pay for it? *U.S. Pharmacist*, 1999;24(9):38-43.
19. Barnes CL, **Corbett AH**, Carter SA. Drug-Induced Hypoglycemia. *U.S. Pharmacist*, 1999;24(2):41-50.

SCIENTIFIC ABSTRACTS

1. Vila T, Cala S, **Corbett A**. Effects of optimal medication therapy management of depression in human immunodeficiency virus (HIV) infected patients on associated virologic and immunologic outcomes. North Carolina Association of Pharmacists, April 2008 [Poster presentation]
2. Brouwer E, **Corbett A**, Napravnik S. Poor recall of antiretroviral use among patients infected with HIV. North Carolina Association of Pharmacists, April 2007 [Poster presentation].
3. Brown K, **Corbett A**, Hosseinipour M, McLeod H, Kashuba ADM. The relationship between drug metabolizing enzyme and drug transporter genotypes and nevirapine exposure in HIV-infected Malawian adults and children. North Carolina Association of Pharmacists, April 2007 [Poster presentation]
4. Karwa R, Correll T, Raasch R, **Corbett A**. Evaluation of dyslipidemia in an HIV population. American Society of Health Systems Pharmacy Midyear Clinical Meeting, Dec 2006 [Poster presentation].
5. Villa T, Cala S, **Corbett A**. Effects of optimal medication therapy management of depression in human immunodeficiency (HIV) infected patients on associated virologic and immunologic outcomes. American Society of Health Systems Pharmacy Midyear Clinical Meeting, Dec 2006 [Poster presentation].
6. **Corbett A**, Hosseinipour M, Nyirenda J, Knayama C, Mshali I, Chinyama S, Lyke A, Rezk N, Hoffman I, Kashbua A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics (PK) Of Trade and Generic Liquid and Split Tablet Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-Infected Malawian Children. 2006 Annual American College of Clinical Pharmacy, St. Louis, MO, Oct 2006 [Poster 408].
7. Pastakia S, **Corbett A**, Raasch R, Napravnik S, and Correll T. Evaluation of continuity of HIV care from the outpatient to the inpatient setting. 2007 American College of Clinical Pharmacy Annual Meeting, St Louis, MO, Oct 2006 [Poster 369].

8. Dumond J, Yeh R, Patterson K, **Corbett A**, Jung B, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba A. First Dose and Steady-State Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- and Post-Exposure Prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, Feb 2006 [Oral Presentation 129].
9. Yeh R, **Corbett A**, Jung B, Rezk N, Bridges A, Min S, Cohen M, Kashuba ADM. First Dose and Steady-State Genital Tract Pharmacokinetics of Zidovudine, Lamivudine, and Efavirenz in HIV-infected Women. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Dec 2005.
10. **Corbett A**, Hosseinipour M, Nyirenda J, Knayama C, Mshali I, Chinyama S, Lyke A, Rezk N, Hoffman I, Kashuba A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics (PK) Of Trade and Generic Liquid and Split Tablet Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-Infected Malawian Children. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 2005 [Poster H-1106].
11. Hosseinipour, MC, **Corbett AH**, Kanyama C, Mshali I, Chinyama S, Phakati S, Rezk N, White S, Hoffman I, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian subjects. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA 2005 [Poster 631].
12. **Corbett AH**, Davidson L, Park J, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB, and Kashuba ADM. Dose separation strategies to overcome the pharmacokinetic (PK) interaction of a triple protease inhibitor regimen containing fosamprenavir (908), lopinavir (LPV), and ritonavir (RTV). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2004 [Poster 611].
13. **Corbett AH**, Eron JJ, Fiscus SA, Rezk N, and Kashuba A. Pharmacokinetics, Efficacy, and Safety of a Triple Protease Inhibitor Salvage Regimen Containing Amprenavir/Saquinavir/Ritonavir. American College of Clinical Pharmacy, Annual Meeting, Atlanta, GA 2003 [Platform Presentation].
14. **Corbett A**, Eron J, Diebold M, Fiscus S, Rezk N, Kashuba A. Short-term Safety and Efficacy of An Amprenavir [APV] /Saquinavir [SQV] /Ritonavir [RTV] Salvage Regimen. Infectious Diseases Society of America, Chicago, IL 2002 [Poster 450].
15. **Corbett A**, Eron J, Rezk N, Diebold M, Kashuba A. A Triple Protease Inhibitor [PI] Salvage Regimen of Amprenavir [APV] + Saquinavir [SQV] + Ritonavir [RTV]: Steady State [SS] Pharmacokinetics [PK] and Initial RNA and CD4 Response. World AIDS Conference, Barcelona, Spain 2002 [Poster 4464].
16. Min SS, **Corbett AH**, Rezk N, Fiscus SA, Cohen MS, Kashuba ADM. Differential Penetration of Protease Inhibitors [PI] and Non-Nucleoside Reverse Transcriptase Inhibitors [NNRTI] into the Female Genital Tract [GT]. World

AIDS Conference, Barcelona, Spain 2002 [Poster 5966].

17. Kashuba ADM, Min SS, **Corbett AH**, Rezk N, Cohen MS. Comparison of Protease Inhibitor [PI] and Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI] Concentrations [CONC] in the Male [M] and Female [F] Genital Tract [GT]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington DC, 2002 [Poster 5.3].
18. **Corbett AH**, Rublein JC, Raasch RH. Impact of HIV Genotyping on Choice of Antiretrovirals. ASHP Midyear Clinical Meeting, Las Vegas, NV 2000.
19. **Corbett AH**, Martin TA, Ohi CA. Evaluation of Antimicrobial Use in a Level I Trauma Intensive Care Unit. ASHP Midyear Clinical Meeting, Las Vegas, NV 2000.

HONORS, AWARDS, OFFICES

<i>May 2007</i>	Pam Herriott Award, Univ of North Carolina, Center for AIDS Research
<i>Apr 2007-present</i>	AIDS Clinical Trials Group, Member, Translational Research and Drug Development Scientific Committee
<i>Jan 2006-present</i>	Triangle College of Clinical Pharmacy Secretary/Treasurer Elect (2006) Secretary/Treasurer (2007) President Elect (2008)
<i>Oct 2005-present</i>	American College of Clinical Pharmacy Infectious Diseases PRN Secretary/Treasurer (2005-06) Member (current)
<i>Oct 2005-present</i>	American College of Clinical Pharmacy Awards Committee Vice Chair (2007-2008)
<i>2004</i>	Board Certification in Pharmacotherapy, American College of Clinical Pharmacy
<i>2004</i>	American College of Clinical Pharmacy, Sanofi- Aventis Infectious Diseases Investigator Development Research Award
<i>2002</i>	American College of Clinical Pharmacy Ortho- McNeil Infectious Diseases Research Fellowship

<i>Sept 2002</i>	Infectious Diseases Society of America Travel Grant Award
<i>May 1999</i>	ASHP Student Leadership Award
<i>Jan 1999</i>	DHHS National Innovation in Health Award, Honorable Mention
<i>Fall 1998</i>	ASHP Clinical Skills Competition, Second Place for Campbell University
<i>Spring 1998</i>	Phi Lambda Sigma National Leadership Challenge, Third Place

PRECEPTING/MENTORING:

***UNC School of Pharmacy Honors Program and
UNC School of Pharmacy Infectious Disease Group***

June 2005-May 2007	Leslie Prichard, PharmD
March 2005-present	Emily Brouwer, PharmD
Nov-Dec 2004	Carolina Molina Lowe, PharmD

UNC Hospitals Infectious Diseases Resident

July 2007-present	Lindsay Mayer, PharmD
July 2006-present	Rakhi Karwa, PharmD
July 2005-June 2006	Sonak Pastakia, PharmD
July 2004-June 2005	Will Musick, PharmD, BCPS
Jan 2004-June 2004	Todd Correll, PharmD, BCPS

UNC School of Pharmacy Fellows

July 2007-present	Kevin Brown, PharmD
July 2005-June 2007	Julie Dumond, PharmD
	Kan Lu, PharmD
Sept 2004-June 2005	Lakshmi Vassist, PharmD
July 2003-June 2005	Rosa Yeh, PharmD, BCPS

UNC School of Pharmacy Research Elective

August 2007-present	Ryan Owenby, PharmD candidate
June 2004-present	Jessica Poirier, PharmD candidate
	Vincent Gaver, PharmD candidate

UNC Clinical Scholars Program

May 2004-present	Faculty Mentor
------------------	----------------

UNC Medical Student Research Program

Jan 2004-present	Alison Lyke, PharmD (Holderness Fellowship Recipient)
------------------	--

***UNC School of Pharmacy, Clinical Clerkships
HIV Ambulatory Care Rotation***

Jan 2004-present

Fourth year pharmacy students

COURSE COORDINATOR:

1. Course Number: DPET 810
Course Title: AIDS: Principles, Practices, and Politics
Dates: Jan 2004-present
2. Course Number: PUBH 120
Course Title: AIDS: Principles, Practices, and Politics
Dates: Jan 2004-present (co-coordinator)
3. Course Title: UNC School of Pharmacy, DPET Division
Postdoctoral Fellows Course
Dates: July 2006-present

LECTURER

1. Course Number: PHCY 110
Course Title: Ambulatory Care Elective
Lectures: HIV Therapy
2004-present
2. Course Title: Infectious Diseases Elective
Lectures: HIV Therapy
Opportunistic Infections
Dates: 2002 – present
3. Course Number: PHTH 153
Course Title: Pharmaceutical Approaches to ID Therapy
Lectures: Research Endeavors in Antiretroviral Therapy
Dates: 2004-present
4. Course Number: PHTH 169
Course Title: Problems in Pharmacotherapy
Weekly Facilitator
Dates: 2003-present
5. Course Number: PHTH 101
Course Title: Introduction to Applied Pharmacogenomics
Lectures: Viral Pharmacogenomics
Dates: 2002 – present
6. Course Number: PHTH 114
Course Title: AIDS: Principles, Practices, and Politics
Lectures: Pharmacodynamics of Antiretroviral Therapy
Introduction to HIV Therapy
PK and TDM of Antiretroviral Therapy
Dates: 2003-present
7. Course Number: PHTH 152 (3rd year course)
Course Title: Infectious Diseases Pharmacotherapy
Lectures: Treatment of HIV Infection

- Dates: 2002 - present
8. Course Title: Clinical Skills Laboratory
Weekly Lab Instructor
Dates: 2000 – 2001
9. Course Title: Clinical Skills Laboratory
Lectures: Practical Issues in Administering Antibiotics
Dates: 2000 - 2001
10. Course Title: Women’s Health Issues
Lectures: Menstrual Dysfunction
Dates: 1998 - 1999

JOURNAL REVIEWER

1. Journal of Acquired Immunodeficiency Syndrome (Jan 2004-present)
2. Drugs (Feb 2004 – present)
3. Journal of Infectious Diseases (Feb 2004-present)
3. Expert Opinion in Pharmacotherapy (April 2004-present)
4. Clinical Infectious Diseases (May 2004-present)
5. Antiviral Therapy (Jan 2006-present)
6. Journal of Antimicrobial Chemotherapy (Jan 2006-present)
7. AIDS Research and Human Retroviruses (Jan 2007-present)
8. Future Drugs (Jan 2007-present)

SERVICE

- Oct 2007-present* American College of Clinical Pharmacy
Awards Committee, Vice Chair
- Aug 2007-present* UNC School of Pharmacy
Admissions Committee, Chair
- June 2007-present* Adult AIDS Clinical Trials Group,
Translational Research and Drug Development
Scientific Committee, Member and Pharmacologist
- Oct 2006-present* American College of Clinical Pharmacy
StuNet, College of Pharmacy Liaison
- Oct 2006-present* American College of Clinical Pharmacy
StuNet, IDPRN Liaison
- Aug 2006-present* UNC School of Pharmacy
Scholarship Committee, member
- Oct 2005-present* American College of Clinical Pharmacy
Awards Committee, Member
- Jan 2004-present* UNC School of Pharmacy

	Clinical Discussion Group, Faculty Advisor
<i>June 2005-present</i>	UNC School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Fellowship Steering Committee, Member
<i>Jan 2005-May 2007</i>	UNC School of Pharmacy, Infectious Diseases Group, Chair
<i>Nov 2004-Dec 2005</i>	Adult AIDS Clinical Trials Group, Maintenance of Drug Interaction Tables, Director
<i>Feb 2004-Dec 2006t</i>	Adult AIDS Clinical Trials Group, Opportunistic Infectious Subcommittee, Member
<i>Jan 2004-Dec 2006</i>	Adult AIDS Clinical Trials Group, Pharmacology Committee
<i>July 2004-August 2007</i>	UNC School of Pharmacy, Progressions Committee Member
<i>Feb 2004 – present</i>	<i>iMedOptions.com</i> Capsule Summary Author
<i>July 2003-May 2007t</i>	UNC School of Pharmacy, Class of 2007 Faculty Advisor
<i>Aug 2004-Jan 2005</i>	Kappa Epsilon, UNC Chapter Faculty Advisor
<i>1997 - 1998</i>	ASHP Student Forum Communications Committee
<i>1996 - 1997</i>	SSHP Campbell University, Vice President; Chair- ASHP Midyear Meeting Committee
<i>1997 - 1998</i>	Phi Lambda Sigma, Campbell University, Vice President
<i>1997</i>	Kappa Psi Pharmaceutical Fraternity Vice President Pledge Class; Fund Raising Committee

PRESENTATIONS

1. *Update on HIV*
North Carolina Association of Pharmacists
Annual Convention, RTP, NC
Oct 2007

2. *Antiretroviral Pharmacology*
UNC School of Medicine ID Fellows,
Core Curriculum
Chapel Hill, NC, Oct 2007
3. *Human Papilloma Disease*
Kappa Epsilon, 46th National Convention
Charlotte, NC, July 2007
4. *Antiretroviral Therapy Update*
The University of Texas Health Center
Tyler, TX, June 2007
5. *Significant Paper in HIV*
North Carolina Association of Pharmacists
Research Triangle Park, NC, Oct 2005
6. *Antiretroviral Drug Interaction Update*
Johnson City, TN / Abbott Laboratories, June 2005
7. *Antiretroviral Drug Interaction Update*
East Carolina University / Abbott Laboratories
Greenville, NC, April 2005
8. *Current Choices, Future Options*
Abbott Laboratories
Durham, NC, February 2005
9. *International Issues in Pharmacology of Antiretrovirals*
UNC School of Pharmacy, Division of Pharmacotherapy
Chapel Hill, NC, November 2004
10. *HIV Update*
Southern Regional AHEC, UNC School of Pharmacy
Southern Pines, NC, August 2004
11. *HIV Therapy*
Wake Pharmaceutical Association / Roche Pharmaceuticals
Raleigh, NC, April 2004
12. *Efficacy, Safety, and Pharmacokinetics of An Amprenavir/Saquinavir/Ritonavir
BID Salvage Regimen*
Infectious Diseases Fellows Forum
Naples, FL, April 2002
13. *Efficacy, Safety, and Pharmacokinetics of An Amprenavir/Saquinavir/Ritonavir
BID Salvage Regimen*
UNC AIDS Clinical Trials Unit, Clinical Research Meeting
Chapel Hill, NC, March 2002
8. *Impact of HIV Genotyping on Choice of Antiretrovirals*

UNC Infectious Diseases Conference
Chapel Hill, NC, September 2001
Southeastern Residency Conference
Athens, GA, April 2001

9. *New and Emerging Antifungals*
UNC Hospitals CE Program
Chapel Hill, NC, February 2001
10. *Once Daily Aminoglycosides in Gram Positive Endocarditis*
UNC School of Pharmacy, UNC Hospitals
Chapel Hill, NC, October 2000
11. *Intravenous Line-Related Infections*
UNC School of Pharmacy, UNC Hospitals
Chapel Hill, NC, August, 2000
12. *Pediatric HIV Infections*
Wake Forest University Baptist Medical Center
Winston-Salem, NC, June 2000
13. *Aminoglycoside Resistant Enterococcal Endocarditis*
Wake Forest University Baptist Medical Center
Winston-Salem, NC, May 2000
14. *Evaluation of Antimicrobial Use in a Level I Trauma Intensive Care Unit*
Wake Forest University Baptist Medical Center
Winston-Salem, NC, March 2000
Southeastern Residency Conference
Athens, GA, April 2000
15. *Overview of Antibiotics*
Wake Forest University Baptist Medical Center
Winston-Salem, NC, February 2000
16. *Viral Hepatitis*
Wake Forest University Baptist Medical Center
Winston-Salem, NC, January 2000
17. *Citalopram (Celexa™)...the New SSRI*
Dorothea Dix Hospital
Raleigh, NC, October, 1998
18. *Cefdinir (Omnicef®)*
Drug Information Center
Campbell University, September, 1998